ArticleEuropean journal of medical research2026
Mechanism of ultrasound-guided renal parenchymal injection of MSCs for the treatment of chronic kidney disease: down-regulated SGK1 promotes M2 macrophage polarization.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The SGK1/ENaC axis in renal injury during salt-sensitive hypertension: from sodium sensing to inflammation.Frontiers in immunology · 2026Review
- Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) often progresses to renal fibrosis, leading to irreversible kidney damage and a decline in renal function. This study explores the therapeutic effects of ultrasound-guided mesenchymal stem cells (MSCs) infusion in CKD, focusing on the regulatory mechanism in macrophage polarization and fibrosis regulation.
methodsCKD models were established in Sprague-Dawley rats via intravenous injection of doxorubicin, and MSCs infusion treatment was performed on the renal parenchyma of the model rats under ultrasound guidance. Meanwhile, transforming growth factor beta 1 (TGF-β1)-stimulated HK-2 cells or THP1-derived macrophage were co-cultured with MSCs to establish an in vitro cellular model. RNA sequencing was employed to identify differentially expressed genes. Furthermore, western blotting, immunofluorescence, and ELISA, were carried out to assess fibrosis, inflammation, and macrophage polarization.
resultsUltrasound-guided MSCs infusion into the renal parenchyma effectively alleviated the pathological damage and fibrosis, and promoted M2 macrophage polarization in the renal tissues of CKD model rats. In vitro, co-culture with MSCs also significantly promoted M2 polarization of macrophages, reduced the levels of pro-inflammatory cytokines, and decreased TGF-β1-induced fibrosis in HK-2 cells. Notably, MSCs treatment significantly downregulated serum and glucocorticoid-regulated kinase 1 (SGK1) expression in CKD model rats or cells, while overexpression of SGK1 reversed MSCs-induced M2 macrophage polarization. Mechanistically, MSCs downregulated SGK1 expression to inactivate the downstream nuclear factor kappa-B pathway, which plays a role in inflammation and fibrosis.
conclusionUltrasound-guided MSCs injection into the renal parenchyma provides an efficient and precise therapeutic approach for CKD. MSCs promote macrophage M2 polarization and exert anti-fibrotic effects in CKD by downregulating SGK1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.